Correction to: Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization

Affiliations

• ¹ Respiratory Medicine and National Cystic Fibrosis Reference Center, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. dominique.hubert@aphp.fr.
• ² Pediatric Respiratory Diseases and Cystic Fibrosis Center, Rouen University Hospital, INSERM CIC1404, EA 2656 UNI ROUEN, Normandy University, Rouen, France.
• ³ Department of Biostatistics and Clinical Research, Rouen University Hospital and INSERM U 1018, University of Rouen, Rouen, France.
• ⁴ Independent Consultant, Boston, MA, USA.
• ⁵ Vertex Pharmaceuticals (France), Paris, France.
• ⁶ Vertex Pharmaceuticals (Europe) Limited, London, UK.
• ⁷ Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
• ⁸ Cystic Fibrosis Center, Hôpital Robert Debré, Assistance Publique-Hôpitaux de Paris, Paris, France.
• ⁹ Respiratory Medicine and National Cystic Fibrosis Reference Center, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
• ¹⁰ Physiology Department, AP-HP Centre-Université de Paris, Hôpital Cochin, Paris, France.